Gesynta Pharma AB

Swedish biotech Gesynta ‘now has the financial runway’ to further study its lead asset GS-248 as an investigational treatment for inflammatory conditions with vasculopathies such as digital ulcers and

With its orally bioavailable inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), Glenmark Pharmaceuticals Ltd. is advancing a novel therapeutic target in pain management, an area that ha

IN VITRO DIAGNOSTICS Financings CareDx Inc. Molecular diagnostics firm CareDx Inc. netted $18.8mm through the follow-on public offering of 4.99mm common shares (including full exercise of the over

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in